An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small intestine was reported in a patient who received cilta-cel therapy; numerous genetic alterations were identified ...

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel ...

Peripheral T cell lymphoma, not otherwise specified (PTCL NOS ... Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in your bloodstream.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is. Hodgkin lymphoma involves a type of cancer ...

Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes ...

is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess MB-105's safety and efficacy in approximately 46 ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...

At the AD/PD meeting held last month in Vienna, scientists implicated T lymphocytes—specifically, the cytotoxic, CD8-positive variety—in Alzheimer’s disease. While the modus operandi of these cells in ...